Surrogate markers for time-varying treatments and outcomes

about

University of Pennsylvania 7th annual conference on statistical issues in clinical trials: Current issues regarding the use of biomarkers and surrogate endpoints in clinical trials (morning panel discussion).

P2860

Q40848813-D55FCECE-F1E2-48ED-BDF7-CFC34BCEAEB2

P2860

Surrogate markers for time-varying treatments and outcomes

Item

http://www.wikidata.org/entity/Q35862680

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Surrogate markers for time-varying treatments and outcomes

@ast

Surrogate markers for time-varying treatments and outcomes

@en

type

Item

label

Surrogate markers for time-varying treatments and outcomes

@ast

Surrogate markers for time-varying treatments and outcomes

@en

prefLabel

Surrogate markers for time-varying treatments and outcomes

@ast

Surrogate markers for time-varying treatments and outcomes

@en

P1476

Surrogate markers for time-varying treatments and outcomes

@en

P2093

Alisa J Stephens-Shields

http://www.w3.org/2001/XMLSchema#string

Dylan S Small

http://www.w3.org/2001/XMLSchema#string

Edward H Kennedy

http://www.w3.org/2001/XMLSchema#string

Jason A Roy

http://www.w3.org/2001/XMLSchema#string

Jesse Y Hsu

http://www.w3.org/2001/XMLSchema#string

Marshall M Joffe

http://www.w3.org/2001/XMLSchema#string

P2860

Identifiability and exchangeability for direct and indirect effects

Estimating causal effects of treatments in randomized and nonrandomized studies.

Evaluating principal surrogate endpoints with time-to-event data accounting for time-varying treatment efficacy

Principal stratification in causal inference

An experimental design for the development of adaptive treatment strategies.

Dynamic treatment regimes: technical challenges and applications

A bayesian approach to surrogacy assessment using principal stratification in clinical trials.

ASSESSING SURROGATE ENDPOINTS IN VACCINE TRIALS WITH CASE-COHORT SAMPLING AND THE COX MODEL.

Surrogate markers in HIV disease.

Surrogate endpoints in clinical trials: definition and operational criteria.

P304

309-316

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1740774515583500

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-05-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25948621

http://www.w3.org/2001/XMLSchema#string

P932

4506229

http://www.w3.org/2001/XMLSchema#string

Surrogate markers for time-varying treatments and outcomes

about

P2860

P2860

Surrogate markers for time-varying treatments and outcomes

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P932